Valuation: Apogee Therapeutics, Inc.

Market Cap 10.01B 8.76B 8.07B 7.49B 14.23B 954B 14.42B 96.61B 37.6B 468B 37.57B 36.75B 1,624B P/E 2026 *
-30.9x
P/E 2027 * -23.9x
Enterprise Value 9.03B 7.91B 7.28B 6.76B 12.83B 861B 13.01B 87.16B 33.92B 423B 33.9B 33.15B 1,465B EV / Sales 2026 *
993x
EV / Sales 2027 * 741x
Free-Float
90.89%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Apogee Therapeutics, Inc.

1 day+0.02%
1 week+0.59%
Current month+0.59%
1 month+60.84%
3 months+60.32%
6 months+69.11%
Current year+76.89%
1 week 132.7
Extreme 132.695
133.87
1 month 81.04
Extreme 81.04
133.87
Current year 60.35
Extreme 60.35
133.87
1 year 34.34
Extreme 34.34
133.87
3 years 14.19
Extreme 14.19
133.87
5 years 14.19
Extreme 14.19
133.87
10 years 14.19
Extreme 14.19
133.87
Manager TitleAgeSince
Chief Executive Officer 36 01/09/2022
Director of Finance/CFO 60 01/01/2023
Chief Tech/Sci/R&D Officer - 01/05/2023
Director TitleAgeSince
Director/Board Member 54 22/06/2023
Director/Board Member 62 01/06/2023
Director/Board Member 36 01/06/2023
Date Insider Type Main position Quantity % Market Cap.
07-01Fiscal year

Chief Technology Officer

13,750 0.0246%
06-22Sell

Chief Executive Officer

-80,000 0.1429%
06-22Sell

Chief Technology Officer

-26,400 0.0471%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%+0.59%+240.25% - 10.01B
-0.16%+6.63%+4.30%+10.86% 50.25B
-0.61%+1.43%+418.03%+619.82% 40.39B
+0.79%+8.45%+28.99%-3.35% 34.38B
-1.37%+7.08%+26.62%+60.98% 34.4B
-4.19%-1.84%+3.76%+32.17% 26.32B
+0.06%+0.82% - - 16.64B
-2.15%+4.25%+73.12%+134.40% 16.14B
+1.46%+1.69%+15.66%+22.88% 13.71B
+1.05%+5.21%+99.66%+99.66% 13.75B
Average -0.50%+3.28%+101.15%+122.18% 25.6B
Weighted average by Cap. -0.60%+3.90%+101.45%+140.68%

Financials

2026 *2027 *
Net sales 9.09M 7.96M 7.33M 6.81M 12.93M 867M 13.1M 87.78M 34.16M 426M 34.14M 33.39M 1.48B 12.5M 10.95M 10.08M 9.36M 17.77M 1.19B 18.01M 121M 46.97M 585M 46.94M 45.91M 2.03B
Net income -318M -278M -256M -238M -451M -30.29B -458M -3.07B -1.19B -14.87B -1.19B -1.17B -51.55B -416M -365M -336M -312M -592M -39.72B -600M -4.02B -1.56B -19.5B -1.56B -1.53B -67.6B
Net Debt -980M -858M -790M -733M -1.39B -93.43B -1.41B -9.46B -3.68B -45.86B -3.68B -3.6B -159B -740M -648M -597M -554M -1.05B -70.61B -1.07B -7.15B -2.78B -34.66B -2.78B -2.72B -120B
Logo Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is advancing novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. APG777, the Company’s most advanced program, is being initially developed for the treatment of AD. With four validated targets in its portfolio, it is seeking to achieve efficacy and dosing through monotherapies and combinations of its novel antibodies. Its most advanced programs are APG777, APG990, APG333, and APG808. APG990 is an SQ extended half-life mAb that utilizes advanced antibody engineering to target OX40L. APG333 is a fully human mAb against thymic stromal lymphopoietin (TSLP). APG808 is an SQ extended half-life mAb targeting IL-4Ra. APG279 is for the dual inhibition of OX40L and IL-13.
Employees
261
Date Price Change Volume
07/07/26 $133.52 +0.01% 28,951
06/07/26 $133.50 +0.44% 1,595,460
02/07/26 $132.91 +0.11% 2,998,799
01/07/26 $132.77 +0.03% 3,598,433
30/06/26 $132.73 +0.09% 5,436,413
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
133.50USD
Average target price
130.53USD
Spread / Average Target
-2.23%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APGE Stock